A report by the Center for Disease Control (CDC) revealed that between 2015 and 2016 overdose deaths involving synthetic opioids had doubled in the US, resulting in President Trump declaring the opioid crisis as a public health emergency. Whilst America continues to rank top for opioid abuse, over 100 people were killed in the UK in 2017 due to fentanyl alone. The BBC reported that nearly 24 million opioids were prescribed in the same year within the UK, a rise of 10 million from 2007. According to a new NPR and Ipsos poll, 56 percent of Americans think that pharmaceutical companies should be held responsible for making the opioid crisis in the USA worse.
Previously these companies have been accused of blatantly ignoring the abuse and illegal distributions of their drugs, now opioid makers and distributors in the USA face increasing legal consequences — in the forms of lawsuits, fines, and charges — for their involvement in today’s drug overdose crisis, which is the deadliest in US history.
Randox Toxicology offer the most comprehensive drugs of abuse test menu across multiple forensic matrices including whole blood, urine and oral fluid. Our level of expertise in toxicology research and development allows us to adapt quickly to the ever-changing market influences and develop assays with optimum target compounds and excellent specificities for current and novel drug trends.
Utilising our revolutionary Biochip Array Technology, Randox Toxicology’s DoA ULTRA and NPS II panels detect designer opioids and fentanyl. The multi-analyte testing platform allows toxicologists to achieve a complete immunoassay profile in the initial screening phase from a single sample, offering CVs typically less than 10%.
For more information about our DoA ULTRA and NPS II panels, visit us at SAT 2nd – 3rd May, Houston, Texas or email email@example.com or visit www.randoxtoxicology.com